Expectations trend
FY2028 · fiscal year ending 2028-09-27 · fmp
Symbotic Inc (SYM)
NASDAQIndustrialsIndustrial - MachinerySnapshot 2026-11-04
$35.04-6.58%
Close 2026-11-05 · 1-day change
NASDAQIndustrialsIndustrial - MachinerySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.83 → 0.85 EPS · FY ending Sep 27, 2028 · 7 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 7; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for SYM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EBITDA expands with profitability | Profitability expands with rising adjusted EBITDA. | Improving | EBITDA margin contracts meaningfully below recent levels | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-27 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 23, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
SYM is a growth-oriented industrial automation business, with a thesis tied to wider system deployments and better operating margins. The thesis is on watch: recent results show progress, but performance remains below its industry cohort and the business is still loss-making overall.
Valuation is expensive versus peers and has risen recently. The expectations gap is close to aligned, so the evidence does not point to a large mismatch between expectations and the operating setup. The priced-in assessment is tagged as justified, with low measured fragility.
Near term, revenue and operating income improved from the first to the second quarter of 2026, in line with management’s focus on deployments and profitability. The expanded Walmart agreement is a meaningful customer milestone, though evidence for broader customer expansion is limited. Guidance cuts, erratic earnings surprises, peer misses, and a sector headwind remain risks.
Over the next few quarters, the thesis depends on continued deployment growth and further improvement in profitability, without a guidance cut. Sector signals also matter: continued strong results from industrial bellwethers could support the backdrop, while misses or lower guidance could remove that support. The Walmart expansion is a specific milestone, but the evidence does not establish how much it will contribute over time.
For the next 1 to 3 years, SYM has evidence of execution progress and a notable customer expansion, but its expensive valuation, loss-making status, high risk, and weaker industry-relative performance leave the long-term thesis conditional. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Cash from operations improves from $191M to $261M in two quarters. |
| Intact |
| Cash from operations falls below $200 million in 2026-Q2 |
Cash from operations: $-147.297M FY2026-Q3; GAAP. Published target: >= $260 million. The stored target says 2026-Q2; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Aug 5, 2026-147,297,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows to about $710M in Q3 2026 | A primary condition in Symbotic Inc's published investment case. The stated target is >= $710 million. | Intact | Revenue falls below $600 million in 2026-Q3 | Revenue: $720.838M FY2026-Q3; GAAP. Published target: >= $710 million. The target does not explicitly identify fiscal versus calendar quarters. Aug 5, 2026720,838,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.83 → $0.85 · observed estimates
$4.51B → $4.52B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-28 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-09-29 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-09-30 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-01 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-02 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-03 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-04 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-05 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-06 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-07 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-08 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-09 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-10 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-11 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-12 | $0.83 | $4,509,787,999 | 5 / 9 |
| 2026-10-13 | $0.86 | $4,509,787,999 | 5 / 9 |
| 2026-10-14 | $0.86 | $4,509,787,999 | 5 / 9 |
| 2026-10-15 | $0.86 | $4,510,104,048 | 5 / 9 |
| 2026-10-16 | $0.86 | $4,510,104,048 | 5 / 9 |
| 2026-10-17 | $0.86 | $4,510,104,048 | 5 / 9 |
| 2026-10-18 | $0.86 | $4,510,104,048 | 5 / 9 |
| 2026-10-19 | $0.86 | $4,510,104,048 | 5 / 9 |
| 2026-10-20 | $0.86 | $4,510,104,048 | 5 / 9 |
| 2026-10-21 | $0.86 | $4,510,104,083 | 6 / 10 |
| 2026-10-22 | $0.86 | $4,510,104,083 | 6 / 10 |
| 2026-10-23 | $0.85 | $4,521,751,621 | 6 / 10 |
| 2026-10-24 | $0.85 | $4,521,751,621 | 7 / 11 |
| 2026-10-25 | $0.85 | $4,521,751,621 | 7 / 11 |
| 2026-10-26 | $0.85 | $4,521,751,621 | 7 / 11 |
| 2026-10-27 | $0.85 | $4,521,751,621 | 7 / 11 |
| 2026-10-28 | $0.85 | $4,521,751,621 | 7 / 11 |
| 2026-10-29 | $0.85 | $4,521,751,621 | 7 / 11 |
| 2026-10-30 | $0.85 | $4,521,751,621 | 7 / 12 |
| 2026-10-31 | $0.85 | $4,521,745,939 | 7 / 12 |
| 2026-11-01 | $0.85 | $4,521,745,939 | 7 / 12 |
| 2026-11-02 | $0.85 | $4,521,745,939 | 7 / 12 |
| 2026-11-03 | $0.85 | $4,521,745,939 | 7 / 12 |
| 2026-11-04 | $0.85 | $4,521,745,939 | 7 / 12 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 10 Buy / Strong Buy · 5 Hold · 3 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.